Skip to main content

Momelotinib

Details of the Drug
Generic Name:
Momelotinib
Drug Type:
Janus kinase (JAK) inhibitor
How the Drug is Given:

By mouth

Names:
Momelotinib
Ojjaara

Indications and Usage

Momelotinib is indicated for the treatment of intermediate or high-risk myelofibrosis (MF), including primary MF or secondary MF [post-polycythemia vera (PV) and post-essential thrombocythemia (ET)], in adults with anemia.

Side effects needing medical attention

The most common adverse reactions are thrombocytopenia, hemorrhage, bacterial infection, fatigue, dizziness, diarrhea, and nausea. 

For information on how to manage the costs of drug therapy, please see Financial Support, or to speak with an Information Specialist, call (800) 955-4572.